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Background: The evaluation of intravitreal bevacizumab treatment for delayed radiation 
maculopathy and papillopathy after irradiation for maxillary sinus cancer.
Case report: A patient with radiation maculopathy and papillopathy was treated with intravitreal 
bevacizumab (1.25 mg). Main outcome measures included fundus photography, angiography, 
and optical coherence tomography (OCT). Two weeks after intravitreal bevacizumab, visual 
acuity improved from 0.4 to 1.2. Fundus examination revealed decreased disc swelling, peri-
papillary hemorrhage, and macular edema. OCT demonstrated complete resolution of serous 
retinal detachment. At the 12-month follow-up, there was no exudation recurrence. No ocular 
or systemic side effects were observed.
Conclusion: Intravitreal bevacizumab can be used to treat radiation maculopathy and 
  papillopathy. Antivascular endothelial growth factor therapy may decrease tissue injury   associated 
with radiation vasculopathy.
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Introduction
Radiation maculopathy and papillopathy are complications after radiotherapy for 
intracranial, skull base, and paranasal sinus tumors. Macular edema and serous retinal 
detachment associated with radiation maculopathy may lead to severe visual loss. 
Although the natural history of radiation papillopathy may be more favorable than 
previously assumed,1 any cases associated with underlying vascular disorders are more 
likely to be aggressive2 and there is still no evidence-based treatment for radiation 
papillopathy. More recently, there have been isolated reports of intravitreal bevaci-
zumab (Avastin®; Genentech Inc, San Francisco, CA) for radiation optic neuropathy 
or maculopathy secondary to plaque radiotherapy.3–5 Here, a case of delayed radiation 
maculopathy and papillopathy secondary to irradiation for maxillary sinus cancer that 
was successfully treated with intravitreal bevacizumab is reported.
Case report
A 73-year-old male presented with acute decrease in vision in the left eye 6 years after 
irradiation therapy for maxillary sinus cancer. The patient had a history of irradiation 
with a dose of 50–55 Gy in 1.8–1.9 Gy fractions to the cancer without invasion into 
eye and orbit. Treatment was performed with an anterior and lateral pair of 45° wedged 
beams. The patient had no diabetes mellitus or vascular disease. On presentation, his 
best-corrected visual acuity was 1.2 OD and 0.4 OS. Ophthalmoscopy was normal in 
the right eye but showed optic disc swelling with peripapillary hemorrhage, retinal Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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exudates, and intraretinal microangiopathy in the left eye 
(Figure 1A). The corresponding fluorescein angiogram (FA) 
revealed optic disc and macular edema, capillary nonperfu-
sion, microaneurysms, and vascular leakage (Figure 1B). 
Optic coherence tomography (OCT) demonstrated serous 
retinal detachment (SRD) (Figure 1C).
The patient was suspected to have radiation maculopathy 
and papillopathy in the left eye. Intravitreal bevacizumab 
(1.25 mg in 0.05 mL) was provided to reduce vascular 
hyperpermeability and intraretinal neovascularization. Two 
weeks after the administration, visual acuity improved to 
20/20 with resolution of SRD. Two months after admin-
istration, a color photograph showed decreased optic disc 
swelling, hemorrhage, and exudates (Figure 2A). OCT 
demonstrated complete regression of SRD (Figure 2C). 
The corresponding FA revealed markedly reduced macular 
edema, decreased intraretinal microangiopathy, and vascular 
leakage (  Figure 2B). These findings were maintained over 
12 months and at the last follow-up (Figure 3A–C).
Discussion
Radiation-induced retinopathy, maculopathy, and papillopa-
thy are serious complications of head and neck radiotherapy. 
Takeda et al have suggested that radiation dose and area 
irradiated are the most important factors in the development 
of radiation retinopathy.6 The results in that study showed 
that 8/14 (57%) eyes that received 50 Gy or more, over 60% 
or more of the area of the retina, developed severe retinal 
  complications.6 Parsons et al also indicated that, in the dose 
range 45–50 Gy, 8/15 (53%) eyes studied developed retinopa-
thy and there was an increased risk of injury among patients 
who received fractional doses of over 1.9 Gy.7 Kim et al 
reported that 63/93 (67.7%) patients who received 70 cobalt 
Gy equivalents (CGEs) developed papillopathy a median of 
1.5 years after irradiation.1 Demizu et al found that the maxi-
mum dose to the optic nerve (.110 GyE3) was significant for 
the occurrence of radiation-induced optic neuropathy.8 Taking 
this into consideration, in this case with a dose of 50–55 Gy 
in 1.8–1.9 Gy fractions over 50% of the area of the retina, 
radiation damage to the macula and optic nerve might be mild 
and the clinical findings might support that view.
Intravitreal bevacizumab has been used in the treat-
ment of age-related macular degeneration,9 retinal vein 
occlusion,10 and diabetic retinopathy11 as it inhibits the 
formation of abnormal blood vessels and reduces vascular 
hyperpermeability from vascular cell damage. Hopewell has 
noted that radiation injury in the central nervous system is 
a consequence of vascular rather than neural cell damage.12 
Radiation papillopathy and maculopathy represent disc swell-
ing, peripapillary hemorrhage, hard exudates,   intraretinal 
Figure 1 (A) Before bevacizumab treatment, the color fundus photograph shows 
optic disc swelling, peripapillary hemorrhage, retinal exudates and microangiopathy. 
(B) Fluorescein angiography demonstrates optic disc and macular edema, capillary 
nonperfusion,  and  microaneurysms.  (C)  Optical  coherence  tomography  (OCT) 
reveals serous retinal detachment.
Figure  2  (A)  Two  months  after  treatment  with  intravitreal  bevacizumab,  the 
color  fundus  photograph  shows  a  decrease  of  optic  disc  swelling,  peripapillary 
hemorrhage, retinal exudates and microangiopathy. (B) Fluorescein angiography 
demonstrates improvement of optic disc and macular edema, and microaneurysms. 
(C) Optical coherence tomography (OCT) reveals complete resolution of serous 
retinal detachment.
Figure 3 (A) Twelve months after treatment, the color fundus photograph shows 
a  well-defined  optic  disc  margin  with  resolution  of  peripapillary  hemorrhage. 
(B) Fluorescein angiography demonstrates persistent decreased microangiopathy 
and vascular leakage. (C) Optical coherence tomography (OCT) reveals sustained 
resolution of serous retinal detachment.Clinical Ophthalmology
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edema, subretinal fluid, and capillary nonperfusion by a 
  radiation-damaged microvasculature. Thus, intravitreal 
bevacizumab may be a reasonable choice for radiation papil-
lopathy and maculopathy, although the severe forms may 
need more aggressive therapy.
Rapid and sustained resolution of radiation maculopathy 
and papillopathy by intravitreal bevacizumab may be a con-
sequence of prompt reduction of vascular hyperpermeability 
and prolonged suppression of retinal neovascularization. 
A recent study has shown that intravitreous ranibizumab 
(Lucentis®; Genentech, San Francisco, CA) can be used for 
radiation maculopathy.13 Because ranibizumab is in the form 
of smaller molecules with rapid wash-out, the drug may need 
repeated monthly injections and consequently increase the 
opportunity for adverse events such as endophthalmitis and 
retinal detachment. In addition, the costs of ranibizumab are 
much higher than bevacizumab. Therefore, the longer acting 
and less expensive bevacizumab therapy may be best for the 
treatment of radiation vasculopathy, although risk–benefit 
comparisons are still needed.
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